Fei Wu

机构：Harbin Medical University, Second Affiliated Hospital of Harbin Medical University, Second Affiliated Hospital of Jilin University · ORCID：0000-0001-5388-0003

发表论文 218 篇 · 总被引 3329 次 · h-index 31

代表论文

• Preclinical evaluation of antitumor activity and toxicity of TROP2-specific CAR-T cells for treatment of triple-negative breast cancer (2025 · Journal for ImmunoTherapy of Cancer · 被引 7)
• WWP1–SHARP1–C/EBPβ positive feedback loop modulates development of metabolic dysfunction–associated steatotic liver disease (2025 · Metabolism · 被引 6)
• Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial. (2025 · Journal of Clinical Oncology · 被引 5)
• Extremely High Systemic Immune Inflammation Levels Increase the Risk of All-Cause and Cardiovascular Mortality in Postmenopausal Women (2025 · International Journal of Women s Health · 被引 5)
• Research trends and highlights in PD-1/PD-L1 inhibitor immunotherapy in lung cancer: a bibliometric analysis (2025 · Discover Oncology · 被引 4)
• Diseases burden and trends of bladder cancer attributable to behavioral and metabolic factors among global and Chinese population, 1990–2021: results from the global burden of disease study 2021 (2025 · Journal of Health Population and Nutrition · 被引 3)